The Phadia 200 quantifies clinically relevant antibodies in blood and can perform up to 700 different ImmunoCAP and EliA tests.

The company has developed a suite of tests designed to measure immunoglobulin E and immunoglobulin G levels for allergy and dietary wellness testing.

In a study, Medical Research Council scientists demonstrated that a test that uses flow cytometry and looks for the CD63 protein in mast cells had 98 percent specificity.

ALK will market Rellergen's Bio-IC lab-on-a-chip technology to more than 190 hospitals in China. The technology uses a blood sample to screen up to 20 different allergens.

United Allergy Services, itself facing a separate false claims suit, alleges it has suffered $200 million in lost profits due to anti-competitive efforts by Quest and other companies.

The deal is anticipated to increase diagnostics' share of PerkinElmer's business to about 38 percent of total revenues from the current 30 percent. 

The French firm said that the funds will go toward international development and the marketing of the company's autoimmunity, allergy, and theranostic products. 

The firms will develop a test to measure total IgE in human tears for diagnosing allergic conjunctivitis.

The companies will provide allergy diagnosis and testing services to clinicians, hospitals, and private laboratories in Southeast Asia.